Related Experiment Video
Updated: Aug 4, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Management of factor VIII inhibitors: evolution and current status
1Department of Haematology, University Hospital of Wales, Cardiff, UK.
Haemostasis
|January 1, 1992
Summary
Managing factor VIII inhibitors in hemophilia involves treating bleeds and inducing tolerance. New methods like recombinant activated factor VII show promise for hemostasis, while immune therapies offer variable success in managing this complication.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Factor VIII inhibitors are a significant complication in hemophilia management.
- Previous treatments for acute bleeds and immune tolerance have shown variable success.
Purpose of the Study:
- To review current and emerging strategies for managing patients with factor VIII inhibitors.
- To discuss methods for acute bleed management, immune tolerance induction, and risk detection.
Main Methods:
- Review of hemostatic agents including factor VIII concentrates, prothrombin complex concentrates, and recombinant activated factor VII.
- Discussion of immune tolerance induction protocols such as the 'Bonn' and 'Malmö' regimes.
- Consideration of tissue factor for exploiting the extrinsic coagulation pathway.
Main Results:
- Recombinant activated factor VII offers a promising approach for hemostasis with reduced risk of disseminated intravascular coagulation.
- Immune tolerance induction methods yield significant but variable success rates.
- Factor VIII concentrates remain the preferred, though often unavailable, treatment for acute bleeds.
Conclusions:
- Factor VIII inhibitor management is an evolving field with ongoing advancements in treatment strategies.
- While progress is being made, inhibitor complications remain a challenge in hemophilia therapy.
- Newer agents and immunomodulatory approaches are improving patient outcomes.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...